BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29765247)

  • 1. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
    Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
    Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?
    Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Shor A; Tremblay G
    Cancer Manag Res; 2018; 10():1015-1025. PubMed ID: 29765249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.
    Beauchemin C; Cooper D; Lapierre MÈ; Yelle L; Lachaine J
    Onco Targets Ther; 2014; 7():1101-10. PubMed ID: 24971020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
    Petrelli F; Barni S
    Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
    Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
    Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials.
    Liu L; Chen F; Zhao J; Yu H
    Bull Cancer; 2016 Apr; 103(4):336-44. PubMed ID: 26874974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
    Li L; Pan Z
    Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Lux MP; Böhme S; Hücherig S; Jeratsch U; Kürschner N; Lüftner D
    Breast Cancer Res Treat; 2019 Aug; 176(3):495-506. PubMed ID: 31065873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
    Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
    Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.
    Beauchemin C; Johnston JB; Lapierre MÈ; Aissa F; Lachaine J
    Curr Oncol; 2015 Jun; 22(3):e148-56. PubMed ID: 26089725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
    Kawalec P; Łopuch S; Mikrut A
    Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.
    Delea TE; Khuu A; Heng DY; Haas T; Soulières D
    Br J Cancer; 2012 Sep; 107(7):1059-68. PubMed ID: 22935581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Untch M; Pérol D; Mayer EL; Cortes J; Nusch A; Cameron D; Barrios C; Delea T; Danyliv A; Mishra N; Gupta R; Pathak P; Fasching PA
    Eur J Cancer; 2024 May; 202():113977. PubMed ID: 38460476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
    Koleva-Kolarova RG; Oktora MP; Robijn AL; Greuter MJW; Reyners AKL; Buskens E; de Bock GH
    Cancer Treat Rev; 2017 Apr; 55():16-25. PubMed ID: 28288388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.
    Chirila C; Odom D; Devercelli G; Khan S; Sherif BN; Kaye JA; Molnár I; Sherrill B
    Int J Colorectal Dis; 2012 May; 27(5):623-34. PubMed ID: 22076612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR
    Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L
    Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.